Founded in 2011 at the Hsinchu Biomedical Science Park, GWOXI has established the R&D center dedicated to developing cell therapy products that address unmet medical needs.
Through modular process design, we have built a pharmaceutical-grade stem cell production platform to advance the future of regenerative medicine.
An allogeneic adipose-derived stem cell therapy for treating osteoarthritis, focusing on pain relief, cartilage regeneration, and knee function improvement.
Product
Preclinical
Phase I
Phase II
Phase III
NDA
Marketed
An allogeneic adipose-derived stem cell therapy for type 1 diabetes, focusing on regulating blood sugar, protecting islets, and reduction of insulin dependence.
Product
Preclinical
Phase I
Phase II
Phase III
NDA
Marketed
A novel autologous adipose-derived stem cell therapy for treating chronic stroke, focusing on angiogenesis, neural differentiation, and motor function improvement.
Product
Preclinical
Phase I
Phase II
Phase III
NDA
Marketed
2025.09.26
Press Releases2025.09.09
Press Releases2025.08.22
Press Releases2025.07.03
Press Releases2025.05.13
Press Releases2025.04.22
Press Releases2025.04.15
Press Releases2025.03.20
Press Releases
26Sep
09Sep
22Aug
03Jul
13May
22Apr
15Apr
20Mar
Licensing Transactions are a common collaboration model in the biotech and pharmaceutical industry.
With advances in medical science, the ways we treat disease are continuously evolving.
INCI name serves as a trusted resource for the cosmetics industry and researchers, helping ensure consumer safety and transparency.
